-
The market of anti-influenza Chinese medicinal materials fluctuates, where will the market go?
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];Since November this year, with the repeated epidemic and the enthusiasm of the people for drug reserves, anti-influenza Chinese medicinal materials have been sold for two times, and the market of many varieties has risen.
-
Briefing on China's pharmaceutical foreign trade in the first three quarters of 2022
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];From January to September 2022, China's trade volume of pharmaceutical products was US$171.
js?cdnversion='+~(-new Date()/36e5)];From January to September 2022, China's trade volume of pharmaceutical products was US$171.
js?cdnversion='+~(-new Date()/36e5)];From January to September 2022, China's trade volume of pharmaceutical products was US$171.
-
The total number of direct settlements for medical treatment across provinces has exceeded 50 million
Time of Update: 2023-01-01
ntenteditable="false" style="border-top:1px dashed rgb(255, 0, 0); color:rgb(255, 255, 255); display:block; font-size:0px; height:0px; left:0px; line-height:0px; margin:0px; padding:0px; position:abs
-
The price of raw materials such as cloves rose, and the profit of Renhe Pharmaceutical declined
Time of Update: 2023-01-01
Cloves, the recent market demand is not large, the attention of merchants is not high, the source of goods is not moving fast, the market remains flat, and the spot price is between 65-66 yuan.
-
Do a good job in implementing the Measures for the Supervision and Administration of Online Drug Sales
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];All provinces, autonomous regions, municipalities directly under the Central Government, and the Drug Administration of the Xinjiang Production and Construction Corps: The Measures for the Supervision and Administration of Online Sales of Drugs (hereinafter referred to as the Measures) were promulgated on September 1, 2022 and came into force on December 1, 2022.
-
In the 100 billion small molecule drug market, the innovation of domestic pharmaceutical companies has begun to enter the harvest period
Time of Update: 2023-01-01
In addition, in early November, Ascletis also announced that ASC61, an oral small molecule inhibitor of PD-L1 independently developed by the company, was approved by the National Medical Products Administration of China (NMPA) to carry out a new drug clinical trial (IND) application for the treatment of advanced solid tumors.
-
In 2023, there will be 4 major trends in the domestic pharmaceutical industry
Time of Update: 2023-01-01
Looking forward to 2023, the author has sorted out four major development trends in the pharmaceutical industry from the perspective of observers: "cost control" is still the main line of pharmaceutical industry policy, domestic substitution is accelerating under the trend of new medical infrastructure, new drug research and development pays more attention to clinical value, and the traditional Chinese medicine industry continues to expand, for industry reference only.
-
Top20 Throat Chinese Proprietary Medicine Announced: Lanqin Oral Liquid, Silver Granules, Liushen Pill...
Time of Update: 2023-01-01
Exclusive variety list In recent years, the total market share of the top 20 proprietary Chinese medicine products in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as Chinese public medical institutions) has exceeded 90%.
-
Salubris Taifawei, Class 1 new drugs rush to the 25 billion market
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On November 22, Salubris announced that the clinical trial application of SAL0119 tablets, an innovative small molecule drug independently developed by the company, was accepted, and the clinical indications currently planned to be developed include active ankylosing spondylitis and moderate to severe active rheumatoid arthritis.
-
On November 29, Chinese medicine stocks were repeatedly active, and many stocks rose to the limit
Time of Update: 2023-01-01
It is reported that previously, Tailong Pharmaceutical issued an announcement that its wholly-owned subsidiary intends to jointly invest with Zhengzhou High-tech Industry Investment Group to establish Longhua Pharmaceutical Industry Fund with a scale of 400 million yuan.
-
The spread of the new crown epidemic in the United States Experts warn that there may be a new peak in the winter
Time of Update: 2023-01-01
The US Centers for Disease Control and Prevention said on the 25th that it is tracking the new subtype XBB of the Omicron strain that has spread in many parts of the United States.
-
Under the epidemic, "the pass is sad", and the life of pharmacies is difficult...
Time of Update: 2023-01-01
Since entering November, the national epidemic situation has changed rapidly, in response to the latest development, many places across the country have tightened control over pharmacy supervision, pharmacy operation and other links, including stopping the sale of "four types of drugs", closing pharmacies for rectification, buying drugs without entering stores and other prevention and control arrangements.
-
2 yuan 20 tablets of antipyretic medicine is fired! The pharmaceutical company is up and down today
Time of Update: 2022-12-30
At noon on December 16, a relevant person from Northeast Pharmaceutical Company said that the company made every effort to organize production and could supply 300 pieces to pharmacies in Shenyang every day.
-
This 5-day, 3-board pharmaceutical stock was fined more than the company's net profit in the first three quarters because of monopoly
Time of Update: 2022-12-30
News on December 13, Northeast Pharmaceutical announced that the company recently received the "Administrative Penalty Notice" issued by the Liaoning Provincial Administration for Market Regulation, because the company violated the anti-monopoly law by selling L-carnitine APIs at unfairly high prices between November 2018 and June 2019, and the company was fined a total of 133 million yuan.
-
Liaoning issued a reminder letter to regulate the price behavior of epidemic prevention drugs and supplies
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];The reporter learned from the Liaoning Provincial Administration for Market Supervision on the 13th that Liaoning issued a reminder letter on regulating the price behavior and competition order of epidemic prevention drug supplies, which requires all relevant operators not to significantly increase the price of "four types of drugs" (antipyretic, cough, antiviral, cold treatment) and antigen detection reagents, household oxygen generators, thermometers and other epidemic prevention drug supplies for any reason.
-
Price gouging, bundling? Wenzhou urban interview warns a large number of pharmaceutical companies!
Time of Update: 2022-12-30
In order to ensure the overall order of the epidemic-related pharmaceutical and equipment market during the adjustment and optimization of epidemic prevention and control policies, the Ouhai District
-
Sinovac Pharma Human Interferon α2b Spray was enrolled in the first subject
Time of Update: 2022-12-30
A randomized, double-blind, single-center, placebo-controlled, dose-escalation safety, tolerability, immunogenicity, and pharmacokinetics of α2b spray administered in healthy adult subjects was conducted in the cooperative Jiangsu Provincial People's Hospital (the First Affiliated Hospital of Nanjing Medical University).
-
In 2029, the out-of-hospital market will reach 160 million yuan, but the "card slot" of pharmaceutical companies is not easy
Time of Update: 2022-12-30
In recent years, not only multinational pharmaceutical companies, including Guangzhou Medicine Baiyunshan, Harbin Pharmaceutical, Xi'an Janssen, Yiling, Buchang, Jiangsu Wanbang, Besunyen and other local pharmaceutical companies have successively cooperated with emerging industry platforms.
-
This pharmaceutical stock will be suspended from trading on the 20th due to the acquisition of assets! There have been many unsuccessful reorganizations
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】Recently, Fengyuan Pharmaceutical issued an announcement that the company is planning to issue shares to purchase assets and raise supporting funds.
-
Guangshengtang 20cm up limit, Chinese medicine 2 plates... On the 16th, the pharmaceutical sector became active again
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】 On December 16, the intraday Chinese medicine sector was active again, Guangshengtang hit the 20cm price limit, China Pharmaceutical achieved 2 con
